1. 148 Antimalarial agents and other immunosuppressants influence BAFF levels in opposite directions in patients with systemic lupus erythematosus. (April 2019) Authors: Hernandez-Breijo, Borja; Gomez, Alvaro; Johansson, Petter; Soukka, Sofia; Parodis, Ioannis Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 150 Antimalarial agents improve physical functioning in patients with systemic lupus erythematosus. (April 2019) Authors: Parodis, Ioannis; Soukka, Sofia; Gomez, Alvaro; Johansson, Petter; Emamikia, Sharzad; Enman, Yvonne; Chatzidionysiou, Katerina Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. (1st February 2019) Authors: Parodis, Ioannis; Emamikia, Sharzad; Gomez, Alvaro; Gunnarsson, Iva; van Vollenhoven, Ronald F.; Chatzidionysiou, Katerina Journal: Expert opinion on biological therapy Issue: Volume 19:Number 2(2019) Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Collaborative Robotics Projects for Adolescents with Autism Spectrum Disorders. Issue 1 (March 2014) Authors: Yuen, Timothy T.; Mason, Lee L.; Gomez, Alvaro Journal: Journal of special education technology Issue: Volume 29:Issue 1(2014) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE. (6th January 2021) Authors: Borg, Alexander; Gomez, Alvaro; Cederlund, Arvid; Cobar, Flordelyn; Qiu, Victor; Lindblom, Julius; Emamikia, Sharzad; Enman, Yvonne; Pettersson, Susanne; Parodis, Ioannis Journal: Rheumatology Issue: Volume 60:Number 9(2021) Page Start: 4205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. (November 2019) Authors: Parodis, Ioannis; Emamikia, Sharzad; Gomez, Alvaro; Gentline, Cidem; Arkema, Elizabeth V; Chatzidionysiou, Katerina; van Vollenhoven, Ronald F Journal: Lancet Issue: Volume 1:Number 3(2019) Page Start: e163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. (27th January 2021) Authors: Lindblom, Julius; Gomez, Alvaro; Borg, Alexander; Emamikia, Sharzad; Ladakis, Dimitris ; Matilla, Joaquin; Pehr, Martin; Cobar, Flordelyn; Enman, Yvonne; Heintz, Emelie ; Regardt, Malin; Parodis, Ioannis Journal: Rheumatology Issue: Volume 60:Number 10(2021) Page Start: 4703 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Issue 7 (4th January 2019) Authors: Parodis, Ioannis; Gomez, Alvaro; Emamikia, Sharzad; Chatzidionysiou, Katerina Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 7(2019) Page Start: 1006 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Issue 7 (4th July 2019) Authors: Parodis, Ioannis; Gomez, Alvaro; Emamikia, Sharzad; Chatzidionysiou, Katerina Journal: Annals of the rheumatic diseases Issue: Volume 78:Issue 7(2019) Page Start: 1006 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0175 PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019) Authors: Parodis, Ioannis; Johansson, Petter; Gomez, Alvaro; Soukka, Sofia; Emamikia, Sharzad; Chatzidionysiou, Katerina Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗